# GALT catalysts: GALECTIN THERAPEUTICS INC PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/galt/catalysts

> GALECTIN THERAPEUTICS INC (GALT) has no upcoming catalysts in this calendar. The latest recorded is the GALECTIN THERAPEUTICS INC earnings report, August 14, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | GALECTIN THERAPEUTICS INC |
| Ticker | GALT (Nasdaq) |
| SEC CIK | 1133416 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/galt |

## Cash runway

Cash $13.3M as of 2026-06-30; quarterly burn $2.4M; about 16.3 months of runway at that rate (XBRL company facts, accession 0001140361-26-032945).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Q4 2024 | [GALECTIN THERAPEUTICS INC topline data readout](https://sec-api.dev/companies/galt/catalysts) | GALT |  | scheduled | "The last patient from the phase 2b stage was randomized in February 2023, and consequently we expect topline results from the IA late in the fourth quarter of 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1133416/000114036124046726/ef20034540_10q.htm)) |
| November 14, 2024 | [GALECTIN THERAPEUTICS INC earnings report](https://sec-api.dev/companies/galt/catalysts) | GALT |  | completed | "Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133416/000114036124046728/ef20038321_ex99-1.htm)) |
| Dec 2024 | [Belapectin topline data readout](https://sec-api.dev/pdufa/belapectin) | GALT |  | scheduled | "The final patient was randomized in February 2023 and the top line efficacy and safety results are expected in December 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1133416/000114036124046726/ef20034540_10q.htm)) |
| March 31, 2025 | [GALECTIN THERAPEUTICS INC earnings report](https://sec-api.dev/companies/galt/catalysts) | GALT |  | completed | "Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133416/000114036125011174/ef20046120_ex99-1.htm)) |
| May 15, 2025 | [GALECTIN THERAPEUTICS INC earnings report](https://sec-api.dev/companies/galt/catalysts) | GALT |  | completed | "Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133416/000114036125019151/ef20048561_ex99-1.htm)) |
| August 14, 2025 | [GALECTIN THERAPEUTICS INC earnings report](https://sec-api.dev/companies/galt/catalysts) | GALT |  | completed | "Galectin Therapeutics Reports Financial Results for the quarter ended June 30, 2025 and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133416/000114036125031041/ef20053791_ex99-1.htm)) |
| November 14, 2025 | [GALECTIN THERAPEUTICS INC earnings report](https://sec-api.dev/companies/galt/catalysts) | GALT |  | completed | "Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133416/000114036125042118/ny20058903x1_ex99-1.htm)) |
| March 31, 2026 | [GALECTIN THERAPEUTICS INC earnings report](https://sec-api.dev/companies/galt/catalysts) | GALT |  | completed | "Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133416/000114036126012158/ef20068722_ex99-1.htm)) |
| May 15, 2026 | [GALECTIN THERAPEUTICS INC earnings report](https://sec-api.dev/companies/galt/catalysts) | GALT |  | completed | "Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133416/000114036126021496/ef20073003_ex99-1.htm)) |
| August 14, 2026 | [GALECTIN THERAPEUTICS INC earnings report](https://sec-api.dev/companies/galt/catalysts) | GALT |  | completed | "Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133416/000114036126032946/ef20080011_ex99-1.htm)) |

## Drugs

- [Belapectin](https://sec-api.dev/pdufa/belapectin): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/galt/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "GALT catalysts: GALECTIN THERAPEUTICS INC PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/galt/catalysts

```bibtex
@misc{secapidev_companies_galt_catalysts_20261116,
  title        = {GALT catalysts: GALECTIN THERAPEUTICS INC PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/galt/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_galt_catalysts_20261116","title":"GALT catalysts: GALECTIN THERAPEUTICS INC PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/galt/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
